Aclarion, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACON | ALINS.PA | CGS.AX | TEM | PMC.F | TNON | |
|---|---|---|---|---|---|---|
| Market cap | 5.02M | 10.82M | 583.48M | 13.79B | 13.54B | 5.14M |
| P/E (TTM) | — | — | 33.8 | — | 86.4 | — |
| Forward P/E | -0.3 | -4.1 | 21.2 | -13,335.1 | — | -0.4 |
| Price/book | 0.3 | -9.3 | 6.9 | 27.5 | 47.0 | -0.1 |
| Dividend yield | — | — | 1.19% | — | 0.36% | — |
| 1-year change | −76.53% | −21.15% | +20.94% | −5.42% | −17.50% | −95.42% |
| Today | −1.14% | 0.00% | +0.90% | −2.81% | +10.73% | +1.06% |
The closest companies by business and industry (Health Information Services). Prices may be delayed up to 20 min.
Latest news
All ACON news ›Bill Achtmeyer joins Matters Graph as first chairman of advisory board
Bill Achtmeyer, the founder of strategy firm Parthenon Group, has joined Matters Graph, a Washington, DC-headquartered buy-side-only commercial due diligence firm, as its inaugural chairman of the advisory board. Achtmeyer will work with…
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
The study compared the non-invasive Nociscan to discography in twenty consecutive patients being evaluated for surgical treatment, across 55 lumbar discs. Nociscan findings successfully identified painful discs, agreeing with discography…
Aclarion to Present at the 20th Annual LD Micro Main Event
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los…
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
The Company emphasizes that this timing update does not change the overall expected duration of the CLARITY trial at this time. CLARITY was intentionally designed with highly optimized inclusion and exclusion criteria to remove confounding…
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30,
Price to book forward of Aclarion, Inc. – NASDAQ:ACONW
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in…
Aclarion announces NYU Langone Health as new clinical site for CLARITY trial
Aclarion (ACON) announced NYU Langone Health as a new clinical site in its CLARITY trial. The CLARITY study is designed to demonstrate Nociscan’... Aclarion announces NYU Langone Health as new clinical site for CLARITY trial Aclarion…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- stocktitan.net2
- consulting.us1
- mykxlg.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.